Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, A Multicenter, Double-blind, Randomized, Placebo-controlled Study Verify the Efficacy and Safety of Ansofaxine Hydrochloride Extended-release Tablets for Major Depressive Disorder

NCT04853407 is registered in ClinicalTrials.gov with Luye Pharma Group Ltd. as lead sponsor.

NCT NCT04853407
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04853407 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, A Multicenter, Double-blind, Randomized, Placebo-controlled Study Verify the Efficacy and Safety of Ansofaxine Hydrochloride Extended-release Tablets for Major Depressive Disorder
Lead sponsor
Luye Pharma Group Ltd.
Phase
Phase 3
Overall status
Completed
Start date
December 5, 2018
Completion date
December 24, 2020
Enrollment
558 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

major depressive disorder (mdd)